GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

This trial (called GATE1) is testing a three-drug combination — pirtobrutinib, rituximab, and venetoclax — as a first-line treatment for mantle cell lymphoma, a type of blood cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with mantle cell lymphoma (confirmed by biopsy with specific genetic markers) - Your cancer cells test positive for CD20 - You have never received treatment for mantle cell lymphoma (except a short course of steroids for urgent symptom relief) - You have symptoms or signs that mean treatment is needed (e.g., B symptoms, enlarging lymph nodes, low blood counts) - You are in reasonably good health (ECOG 0–2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have central nervous system involvement by lymphoma - You have already received systemic therapy for mantle cell lymphoma - Your blood counts or organ function do not meet the required thresholds Talk to your doctor to see if this trial is right for you.